Biomea Fusion Inc. has announced the filing of a prospectus supplement with the U.S. Securities and Exchange Commission $(SEC.UK)$ dated June 17, 2025, relating to an underwritten offering. The offering includes 19,450,000 shares of common stock, pre-funded warrants for 550,000 shares, and accompanying warrants for up to 20,000,000 shares. The company anticipates net proceeds of approximately $37.1 million, potentially increasing to $42.7 million if underwriters fully exercise their options. The shares and warrants are issued under a shelf registration statement filed with the SEC in October 2022. The amended underwriting agreement includes standard representations, warranties, and indemnification obligations.